Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Video Library —July 18, 2018
Categories:
Interview with the InnovatorsThoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Last modified: August 10, 2023